in-pharmatechnologist.com -- Ranbaxy Laboratories is selling its 50 per cent stake in its Japanese joint venture (JV) to its partner Nippon Chemiphar (NC), allowing both companies to independently pursue their generic businesses.
in-pharmatechnologist.com -- Ranbaxy Laboratories is selling its 50 per cent stake in its Japanese joint venture (JV) to its partner Nippon Chemiphar (NC), allowing both companies to independently pursue their generic businesses.
